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Introduction: The Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE)
is a public-private collaboration aiming to develop and test a system for rapid benefit-risk (B/R) monitor-
ing of vaccines, using existing healthcare databases in Europe. The objective of this paper was to assess
the feasibility of using electronic healthcare databases to estimate dose-specific acellular pertussis (aP)
and whole cell pertussis (wP) vaccine coverage.
Methods: Seven electronic healthcare databases in four European countries (Denmark (n = 2), UK (n = 2),
Spain (n = 2) and Italy (n = 1)) participated in this study. Children were included from birth and followed
up to age six years. Vaccination exposure was obtained from the databases and classified by type (aP or
wP), and dose 1, 2 or 3. Coverage was estimated using period prevalence. For the 2006 birth cohort, twohemical
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pean countries using electronic healthcare dataestimation methods for pertussis vaccine coverage, period prevalence and cumulative incidence were
compared for each database.
Results: The majority of the 2,575,576 children included had been vaccinated at the country-specific rec-
ommended ages. Overall, the estimated dose 3 coverage was 88–97% in Denmark (birth cohorts from
2003 to 2014), 96–100% in the UK (2003–2014), 95–98% in Spain (2004–2014) and 94% in Italy (2006–
2007). The estimated dose 3 coverage per birth cohort in Denmark and the UK differed by 1–6% compared
with national estimates, with our estimates mostly higher. The estimated dose 3 coverage in Spain dif-
fered by 0–2% with no consistent over- or underestimation. In Italy, the estimates were 3% lower com-
pared with the national estimates. Except for Italy, for which the two coverage estimation methods
generated the same results, the estimated cumulative incidence coverages were consistently 1–10%
lower than period prevalence estimates.
Conclusion: This study showed that it was possible to provide consistent estimates of pertussis immuni-
sation coverage from the electronic healthcare databases included, and that the estimates were compa-
rable with the national estimates.
 2019 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction regional and one national hospital discharge database linked toWhole cell pertussis (wP) vaccines have been available since the
1940s and were effective in reducing the number of pertussis cases
and mortality [1,2]. However, due to common minor adverse reac-
tions and less common severe systemic reactions to wP, acellular
pertussis (aP) vaccines were developed and used from the mid-
1990s [1]. Many countries replaced wP with aP, and Poland is the
only country in Europe where wP vaccine is still included in the
childhood vaccination programme [3].
World-wide, countries provide annual reports on national per-
tussis vaccine coverage estimates to WHO/UNICEF’s Vaccine Pre-
ventable Diseases Monitoring System [4]. Electronic registration
of vaccination is becoming more widespread in Europe, allowing
countries to share vaccine coverage data for further analysis. In a
survey by the European Centre for Disease Prevention and Control
(ECDC) in 2016, 16 out of 27 EU/EEA countries reported that they
had a national or sub-national vaccination information system, 5
countries reported they were piloting a system and 6 countries
said they had plans to set up a system in the future [5]. Collations
of data from these registries and other sources have shown that
pertussis vaccine coverage in Europe is generally above 90%,
although coverage has dropped in some countries in some years
[6,7].
The Accelerated Development of VAccine beNefit-risk Collabo-
ration in Europe (ADVANCE) is a public-private collaboration aim-
ing to develop and test a system for rapid benefit-risk (B/R)
monitoring of vaccines, using existing healthcare databases in Eur-
ope. A series of proof of concept (POC) studies were designed to
assess the processes and system proposed for generating data on
vaccination coverage, benefits and risks required to perform B/R
monitoring. As a preparatory step to these studies, a systematic
approach was used to characterise and assess the eligibility of
these healthcare databases for their use in coverage and B/R stud-
ies [8].
The objective of this paper was to determine the feasibility of
using electronic healthcare databases to estimate dose-specific
vaccination coverage by age and its variation across birth cohorts,
using aP and wP vaccination coverage as an example.
2. Material and methods
2.1. Databases
Nine of the 19 electronic European healthcare databases had
recorded the pertussis vaccines and of these two databases were
not able to provide data within the ADVANCE POC study deadline,
leaving a total of seven databases for this study [8]. There was onert, T. Braeye et al., ADVANCE sy
bases: An example, Vaccine, htvaccination registries from Denmark (Aarhus University Hospital:
AUH and Statens Serum Institut: SSI), one multiregional and one
regional primary healthcare record database from Spain (Database
for Pharmacoepidemiological Research in Primary Care: BIFAP and
the Information System for Primary Care Research: SIDIAP), two
national primary care medical record databases from the UK (The
Health Improvement Network: THIN and Royal College of General
Practitioners Research and Surveillance Centre: RCGP RSC) and one
regional family paediatrician database linked to the Veneto vaccine
registry from Italy (PEDIANET). SSI was the only database that used
the national vaccination register when extracting aP and wP vac-
cines. Details about the extraction, management, transformation,
sharing, and analyses of the data using the ADVANCE systemwork-
flows and methodology (common protocol, common data model
and common analytics) can be found in another paper in this sup-
plement [9]. In response to a survey, the database owners provided
information on database characteristics such as representative-
ness, origin of data, population size, data-availability period,
switch from wP to aP vaccines, historical pertussis vaccine sched-
ules, availability of ATC-codes and doses, how information about
dose was recorded and rounding rules for birth dates due to pri-
vacy (Table 1).
2.2. Study population
The eligible population comprised all children from birth to five
years old, registered in any of the participating databases and iden-
tifiable through a unique anonymised patient-ID and with at least
one day of follow-up during the overall study period: 1st January
1990 to 31st December 2015. Children were eligible for inclusion
in the study population if they entered the database at the age of
one month or younger during the study period (defined as start
of follow-up). We defined end of follow-up, as the date of which-
ever of the following events occurred first: receipt of their pre-
school-entry pertussis booster, 6th birthday, end of study (varied
across databases - see country specific study periods in Table 1),
transferring out from the catchment of the database, or death. Chil-
dren with incomplete dates of birth, start or end of follow-up were
excluded. Rounding of birth dates was allowed.
2.3. Exposure
The exposure of interest was vaccination with any pertussis-
containing vaccine in the study population during follow-up. In
Denmark (AUH, SSI), the vaccine type was recorded at the time
of administration. In the UK, the switch from wP to aP occurred
in October 2004. Vaccines administered prior to 1st Octoberstem testing: Can coverage of pertussis vaccination be estimated in Euro-
tps://doi.org/10.1016/j.vaccine.2019.07.039
Table 1
Characteristics of the seven participating databases.
Country Denmark Spain United Kingdom Italy
Database AUH SSI BIFAP SIDIAP THIN RCGP RSC PEDIANET
Representativeness Regional National Multi-regional Regional National National Regional
Whole Whole Subset Subset Subset Subset Subset
Origin of data Record linkage
between different
registries*
GP and primary care
paediatricians
GP and
paediatricians
GP GP Family
paediatricians
Birth cohorts available for
coverage estimation
2002–
2015
1997–
2014**
2002–2014*** 2005–2015 1990–2015 1990–2015 2006–2007
Switch from wP to aP 1997 1997 1997–2004 1997–2004 2004 2004 1995
Percentage wP of all vaccinations
recorded
0 2.1 1.7 0 64.3 47.7 0
ATC code available (%) 0 100 100**** 0 0 0 0*****
Dose recorded (% missing) Yes
(35.4)
Yes (2.7) Yes (23) Yes (0) Yes (<0.01) No Yes (0)
Dose derived (% missing) Yes (0) Yes (2.8) Yes (2) None None Yes (0) None
Rounding of birthdates None None None Rounded to 1st of
month
Rounded to 1st of
month
Rounded to 1st of
month
Rounded to 15th
of month
AUH: Aarhus University Hospital Denmark; SSI, Statens Serum Institut Denmark; BIFAP: Database for Pharmacoepidemiological Research in Primary Care Spain; SIDIAP,
Information System for Primary Care Research Spain; THIN, The Health Improvement Network UK; RCGP RSC: Royal College of General Practitioners Research and
Surveillance Centre UK; PEDIANET: Family Paediatrician Database Veneto vaccine registry Italy.
* The general practioners register the pertussis vaccinations at the time of administration and afterward the vaccination data are linked to the population data.
** The study period was 1997 to September 2014.
*** The 2002 and 2003 birth cohorts were excluded from the coverage analyses since the vaccine type was unknown for the majority of the vaccines administered.
**** ATC code was derived based on the described antigen combinations, marketed vaccines at every calendar year of vaccination and age at vaccination according to the rules
in the national scheme.
***** Could be derived from coded association information.
H.-D. Emborg et al. / Vaccine xxx (xxxx) xxx 32004 were recorded as wP, vaccines administered in October 2004
were recorded as uP (unknown) and vaccines administered from
1st November 2004 and onwards as aP. In Spain, aP vaccines were
first introduced in 1997 and the switch from wP to aP vaccines
occurred gradually until 2004. From 2005 onwards only aP vacci-
nes were available, which means that the SIDIAP database only
provided aP data (Table 1). In the Spanish BIFAP database, the anti-
gens mentioned in the vaccination code recorded at the time of
each administration was used to determine the vaccine type
administered. In Italy, only aP were administered to the 2006
and 2007 birth cohort (Table 1). In all databases, when the vaccine
type (aP or wP) could not be determined reliably, it was coded uP.
If the dose number was not recorded in the database, it was
derived based on the chronological sequence of administered doses
and the age of the child. A child was assumed to be vaccinated on
the day the vaccine dose was recorded. All records with missing
patient-ID, dates or vaccine type were excluded from analysis.2.4. Statistical methods
Vaccination coverage (per dose) was estimated as the percent-
age of the children in the study population who had received the
specific vaccine dose by a certain age. Pertussis vaccine coverage
was estimated by dose and by age (in weeks) in each birth cohort,
using period prevalence, taking into consideration any children
lost-to-follow-up (PPFU). The PPFU-estimate for children at a certain
age (in weeks) was the number of children vaccinated with the first
dose (D1), second dose (D2), and third dose (D3), respectively,
divided by the total number of children in follow-up at that age
(in weeks). For example, in the 2012 birth cohort, at five weeks
of age, the number of children vaccinated with the first dose
(D1), second dose (D2) and third dose (D3), respectively, was
divided by the total number of children in the 2012 birth cohort
and being follow-up at five weeks of age. At six weeks of age the
total number of children still in the population and vaccinated with
D1, D2 and D3 respectively, was divided by the total number of
children still being followed-up in the 2012 birth cohort aged six
weeks old etc. Thus the numerator and the denominator couldPlease cite this article as: H.-D. Emborg, J. Kahlert, T. Braeye et al., ADVANCE sy
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between different methods to estimate pertussis coverage, for
the 2006 birth cohort in each database the PPFU coverage estimates
were compared with the cumulative incidence (CumInc) of pertus-
sis vaccination. The cumulative incidence was estimated for each
birth cohort as the number of all vaccinated children at a certain
age in weeks divided by the number of eligible children, i.e. those
at the start of the follow-up period.
The age at vaccination per birth cohort, dose and vaccine type
were estimated and presented in Cleveland dot plots as 10%, 50%
(median) and 90% quantiles [10].
To assess the validity of the coverage estimates obtained in this
study, the estimates were compared with the national coverage
estimates that have been published by the public health institutes
in each of the four countries that the databases originated from.
We did not report wP for the THIN-database before 2000,
because birthdates were rounded to 1st of July at extraction, lead-
ing to inaccurate age of vaccination.
3. Results
3.1. Study population
The seven databases that participated showed large variation in
their overall number of eligible persons (0.0097–1.2 millions) and
availability of data during the overall study period: this varied
from 2 to 26 years (Tables 1 and 2). The total study population
across all databases comprised 2.575 million children aged
<6 years (Table 2).
3.2. Pertussis vaccination data
In the BIFAP, RCGP RSC, AUH and SSI databases the vaccine dose
was not recorded reliably for all records and had to be derived.
Only the UK databases could provide a large proportion of data
on wP vaccination coverage.
Across all birth cohorts within a database and across databases
within a country, the majority of children were vaccinated at thestem testing: Can coverage of pertussis vaccination be estimated in Euro-
tps://doi.org/10.1016/j.vaccine.2019.07.039
Table 2
Attrition table of seven databases (AUH and SSI from Denmark, RCGP RSC and THIN from UK, BIFAP and SIDIAP from Spain and PEDIANET from Italy).
Denmark UK Spain Italy Total
AUH SSI THIN RCGP RSC BIFAP SIDIAP PEDIANET
Number of persons (all ages) 1,725,165 7,512,032 13,646,770 3,017,610 7,541,864 7,096,695 9,708 40,549,844
Number of persons born during the birth years of interest
(1990–2015)
499,318 1,822,953 1,616,311 860,411 1,467,618 1,774,085 9,708 8,050,404
Number of persons without follow-up (<1 day of follow-up) 0 31,434 59,933 0 23 92,932 0 184,322
Number of persons with start of follow-up after the age of
1 month
310,765 571,787 1,206,165 814,171 1,174,425 1,213,193 0 5,290,506
Number of persons eligible for analysis 188,553 1,219,732 350,213 46,240 293,170 467,960 9708 2,575,576
AUH: Aarhus University Hospital, Denmark; SSI, Statens Serum Institut, Denmark; RCGP RSC: Royal College of General Practitioners Research and Surveillance Centre, UK;
THIN, The Health Improvement Network, UK; BIFAP: Database for Pharmacoepidemiological Research in Primary Care Spain; SIDIAP, Information System for Primary Care
Research Spain; PEDIANET: Family Paediatrician Database Veneto vaccine registry Italy.
4 H.-D. Emborg et al. / Vaccine xxx (xxxx) xxxrecommended age of vaccination (Fig. 1). However, the 90% quan-
tile for age at vaccination was higher than the recommended age of
vaccination in some cases, indicating that a certain percentage of
individuals in the birth cohorts were vaccinated late.
3.3. Pertussis vaccination coverage for dose 3
The coverage estimates (PPFU) by age for dose 3 (D3) are sum-
marised by database, birth cohort and type of vaccine (aP, wP) in
Fig. 2. The coverage started to increase in all databases at the age
when the D3 was recommended in the country. For example, the
aP D3 for children is recommended at 12 months old in Denmark
and the D3 coverage estimates in AUH and SSI were close to zero
until just before the children were 12 months old, then increasedA: Denmark aP B: UK wP
D: Spain aP
Fig. 1. Median age in weeks, at first (D1), second (D2) and third (D3) dose of whole ce
vaccination for the entire birth cohort. A: aP vaccination from AUH and SSI in Denmark; B
from BIFAP and SIDIAP in Spain; E: aP vaccination from PEDIANET in Italy. The recomm
show every second or third birth cohort only due to limited space. The SSI database provid
the age of 12 month when the aP dose 3 is recommended in Denmark; thus this dose is
Please cite this article as: H.-D. Emborg, J. Kahlert, T. Braeye et al., ADVANCE sy
pean countries using electronic healthcare databases: An example, Vaccine, htrapidly after they were 12 months old to above 80% at 15 months
of age in all birth cohorts. In general, the observed age of the D3-
vaccination was similar across birth cohorts from the same data-
base. Following the steep increase in coverage estimates, little
change was observed until the end of the follow-up period. The dif-
ferences in coverage reached at the end of the follow-up at
72 months old were between 0% and 8% between birth cohorts
within the same database, except for the RCGP RSC and THIN data-
bases. In these databases the differences were 21% and 27%, respec-
tively, with the largest difference observed at the end of follow-up
at 72 months of age (Fig. 2). Spikes at the end of the follow-up were
due to small sample sizes, especially in the younger birth cohorts.
The switch fromwP to aP occurred in 2004 in the UK, therefore, the
2004 birth cohort from RCGP RSC is the only one with a substan-C: UK aP
E: Italy aP
ll (wP) or acellular (aP) pertussis vaccine and the 10% and 90% quantiles for age at
and C: wP and aP vaccination from RCGP RSC and THIN in the UK; D: aP vaccination
ended ages of vaccination are indicated by the vertical lines and shaded areas. We
ed data until September 2014, so that none of the children born in 2014 had reached
missing for the 2014 birth cohort.
stem testing: Can coverage of pertussis vaccination be estimated in Euro-
tps://doi.org/10.1016/j.vaccine.2019.07.039
H.-D. Emborg et al. / Vaccine xxx (xxxx) xxx 5tially lower coverage for both aP and wP in 2004, compared with
the other cohorts that included the switch from wP to aP. This
was not observed in the THIN database since the vaccine type
could not be determined during the switch in 2004.
3.4. Comparison of vaccination coverage estimation methods
We estimated coverage for the 2006 birth cohort in each data-
base as a method, to compare the results with the estimation
methods (PPFU and CumInc). The CumInc estimates were consis-
tently 1–10% lower at the end of follow-up in all databases, except
for PEDIANET, where the two methods generated the same results
(Fig. 3).
3.5. Comparison with national coverage rates
Comparison of national and estimated coverage rates was done
for dose 3. Overall, the estimated coverage was 88–97% (birth
cohorts from 2003 to 2014) in Denmark, 96–100% (2003–2014)
in the UK, 95–98% (2004–2014) in Spain and 94% (2006–2007) in
Italy (Table 3). The estimated coverage in the Danish SSI and
AUH databases differed by 1–4% and 2–6%, respectively, compared
with the national estimates. In the UK THIN and RCGP RSC data-
bases, the estimated coverage differed by 2–5% and 1–6%, respec-
tively, compared with the national estimates. In both Denmark
and UK, our estimates were almost always higher. The estimated
coverage in the Spanish BIFAP and SIDIAP databases differed both
by 0–2% compared to the national estimates with no clear direction
of the deviation. The coverage estimates from the Italian PEDIANET
database were 3% lower than the national estimates.4. Discussion
This study showed that it was possible to provide reliable esti-
mates on pertussis vaccination coverage using data in the seven
participating healthcare databases in four countries. The results
showed that the ages when the pertussis doses were administered
were comparable across up to 26 birth cohorts within the same
database. We observed a steep increase in the period coverage
prevalence estimates for dose 3 at almost the same age in all birth
cohorts within each database. In addition, the observed age at vac-
cination was consistent with the recommended age for vaccina-
tion, as defined in the national guidelines, and the overall
coverages obtained at the end of follow-up (72 months) were com-
parable to the national coverage estimates, which demonstrates
the feasibility of obtaining accurate estimates for vaccination cov-
erage using data from healthcare databases.
In addition to the information on the median age at vaccination,
we also observed variability in age of vaccination, which confirms a
delay in vaccination for a part of the population that has been
reported in several countries [11–14]. The more recent birth
cohorts had shorter follow-up time than the earlier birth cohorts,
because of the retrospective nature of the study, which led to
unequal truncation of follow-up time. For example: at the end of
the study period the oldest child in 2014 birth cohort would be
730 days old (December 2015), and consequently, the median
age for the third dose in this birth cohort would be expected to
be lower than in the earlier birth cohorts because data for any chil-
dren with late vaccination would be truncated in the later birth
cohorts.
A review of the databases that were considered for the inclusion
in this proof of concept study revealed differences in how data
about the vaccine and the vaccine dose administered were
recorded, and the level of information provided, in terms of the
codes used and what free text was used [8]. Despite these differ-Please cite this article as: H.-D. Emborg, J. Kahlert, T. Braeye et al., ADVANCE sy
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administered and the date of vaccination, derive the relevant doses
and to obtain coverage estimates (overall, by birth cohort and age)
close to the national estimates provided by public healthcare
authorities. In the PRISM programme in the USA, DTP, DT and DTaP
vaccination coverage was estimated to be 76% for the third dose,
using data from three claims databases, compared with the esti-
mated 91% vaccination coverage obtained through the National
Immunization Survey, which is a bigger difference than what we
observed [15]. However, previous studies have shown underre-
porting of childhood vaccination coverage when based on vaccina-
tion registers [16,17] and we cannot rule out that pertussis vaccine
coverages was underreported in the databases included in this
study and in the databases used for the national coverage
estimation.
The high level of concordance between our coverage estimates
and the national estimates was not expected because the inclusion
criteria for this study (see Methods section) differed from those
used for the national coverage estimation. We followed the birth
cohorts up to 72 months (6th birthday) whereas most countries
usually select an age closer to the recommended age of vaccination
to be able to estimate vaccination coverage in relation to the
national recommendations for vaccination (see references for
national estimates in Table 3 for further details). In addition, if eco-
logical data (i.e. total number of administered vaccines divided by
the total number of children registered in the census) are used for
national estimations like in Spain -, this could potentially result in
larger deviations from the patient-level estimations used in our
study.
The databases included in our study varied in size, geographical
coverage and healthcare setting. The national registries have a
more stable population with fewer individuals leaving or entering
the database at different time points, compared with, for example
GP databases, where the turnover of patients is expected to be
higher, resulting in incomplete follow-up for a proportion of the
population [8]. This could result in biased prevalence rates, if con-
sidered as complete follow-up, and thus compromise the coverage
estimates [18]. In addition, we cannot rule out that a portion of the
population has very little contact to the healthcare system and
these children may not be registered in the databases and included
in this study. In our study, we estimated vaccination coverage as a
period prevalence, taking into consideration loss-to-follow-up.
This approach can result in lower coverage estimates when vacci-
nated children leave the database faster than unvaccinated chil-
dren and higher coverage estimates when unvaccinated children
leave the database faster than vaccinated children. This could occur
if vaccination schedules differ across regions in the same country,
for example in a multi-regional database setting. However, this is
less likely to be important across regions with homogeneous vac-
cination schedules.
Our results showed that vaccination coverage at the end of
follow-up, estimated using PPFU or CumInc were comparable (0–
10% difference) for the 2006 birth cohorts (Fig. 3). This suggests
that incomplete follow-up did not have a large impact on the cov-
erage estimation in this study, possibly because incomplete follow-
up was limited in this comparison. The inclusion of children who
entered the database only within one month of birth limited the
left-censoring, which may reduce bias in coverage estimates since
the youngest children are also those who receive pertussis vaccine
[19]. This inclusion criterion could increase bias in coverage esti-
mation since children who have their first GP visit before one
month of age might be those who are more likely to be vaccinated
and, also, perhaps more likely to be vaccinated in compliance with
the national guidelines [18]. Some of the participating databases
round birth dates to the 1st or the 15th of the birth month which
means that some children will only have two weeks to be enrolledstem testing: Can coverage of pertussis vaccination be estimated in Euro-
tps://doi.org/10.1016/j.vaccine.2019.07.039
A: AUH aP
B: SSI aP
E: THIN wP
F: THIN aP
I: PEDIANET aP
C: RCGP RSC wP
D: RCGP RSC aP
G: BIFAP aP
H: SIDIAP aP
Fig. 2. Pertussis coverage by age for dose 3 estimated as period prevalence (PPFU) by database, birth cohort and type of vaccine (wP or aP). A: AUH, Denmark, aP; B: SSI,
Denmark, aP; C: RCGP RSC, UK, wP; D: RCGP RSC, UK, aP; E: THIN, UK, wP; F: THIN, UK, aP; G: BIFAP, Spain, aP; H: SIDIAP, Spain, aP; I:PEDIANET, Italy, aP.
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Fig. 3. Comparison of the monthly dose 3 pertussis vaccination coverage for 2006 birth cohorts using period prevalence (PPFU) and cumulative incidence (CumInc) methods
from birth up to 6th birthday. A: AUH and B: SSI from Denmark; C: RCGP RSC and D: THIN from the UK; E: BIFAP and F: SIDIAP from Spain; G: PEDIANET from Italy.
H.-D. Emborg et al. / Vaccine xxx (xxxx) xxx 7in the study population and others will have six weeks, which
could potentially exclude a large number of children. This could
also result in misclassification of age. If vaccination adherence
and registration in the database after one month of age were
dependent variables, the two coverage estimation methods would
provide biased, overestimated or underestimated coverage esti-
mates, depending on the direction of the dependency. The data-
base used by SSI to estimate pertussis coverage is similar to the
national vaccination register and consequently only the method
differed between the SSI pertussis coverage estimates and the
national estimates. The AUH, THIN and RCGP RSC databases com-
prise subsets of the data from which the national coverage esti-
mates are derived. Thus these data are not entirely independent
of the national estimates.
It was possible to estimate aP-containing vaccine coverage rates
in all seven participating databases using the two estimationPlease cite this article as: H.-D. Emborg, J. Kahlert, T. Braeye et al., ADVANCE sy
pean countries using electronic healthcare databases: An example, Vaccine, htmethods. However, it was only possible to estimate wP-
containing vaccine coverage before and during the switch from
wP to aP in two databases due to low numbers of registered wP
vaccinations in the remaining five databases where the switch
occurred prior to the study period.
In conclusion, we identified heterogeneity in the characteristics
of the databases, which lead to challenges in defining inclusion cri-
teria and taking incomplete follow-up into account, and thus for
estimating pertussis vaccination coverage. We handled these ele-
ments in a homogenous manner across countries and were, there-
fore able to provide reliable pertussis coverage estimates.
Role of funding source
The research leading to these results received support from the
Innovative Medicines Initiative Joint Undertaking under thestem testing: Can coverage of pertussis vaccination be estimated in Euro-
tps://doi.org/10.1016/j.vaccine.2019.07.039
Table 3
Comparison of estimated database-specific dose 3 pertussis coverage (%) based on period prevalence (PPFU) at the end of follow-up (after 72 months) with the national pertussis
coverage estimates reported by a national authority.
Birth cohort Denmark UK Spain Italy
National* AUH SSI National* RCGP RSC THIN National* BIFAP SIDIAP National* PEDIANET
2003 88 92 90 98 98 97
2004 87 92 89 98 97 96 97
2005 86 90 88 97 98 96 96 98 96
2006 87 92 89 93 98 98 98 96 97 97 94
2007 88 93 91 93 97 98 96 97 96 97 94
2008 89 94 91 93 99 98 97 97 96 97
2009 89 94 92 95 98 98 96 96 96 96
2010 90 94 92 94 98 98 97 97 96 96
2011 89 95 92 95 96 99 97 98 96 96
2012 91 94 92 95 98 99 96 95 96 96
2013 91 97 90 94 100 98 96 97 95 96
2014 91 89 95 98 97 97 97 95 95
Denmark: https://www.ssi.dk/Smitteberedskab/Sygdomsovervaagning/VaccinationSurveillance.aspx?xaxis=Cohort&vaccination=3&sex=3&landsdel=100&show=&datatype=
Vaccination&extendedfilters=False#HeaderText.
UK: https://www.gov.uk/government/publications/cover-of-vaccination-evaluated-rapidly-cover-programme-annual-data.
Spain: http://www.msssi.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/TosFerina.pdf.
Italy: http://www.epicentro.iss.it/temi/vaccinazioni/dati_Ita.asp#pertosse.
AUH: Aarhus University Hospital Denmark; SSI, Statens Serum Institut Denmark; RCGP RSC: Royal College of General Practitioners Research and Surveillance Centre UK;
THIN, The Health Improvement Network UK; BIFAP: Database for Pharmacoepidemiological Research in Primary Care Spain; SIDIAP, Information System for Primary Care
Research Spain; PEDIANET: Family Paediatrician Database Veneto vaccine registry Italy.
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Disclaimer
The results described in this publication are from the proof of
concept studies conducted as part of the IMI ADVANCE project
with the aim of testing the methodological aspects of the design,
conduct and reporting of studies for vaccine benefit-risk monitor-
ing activities. The results presented relate solely to the method-
ological testing and are not intended to inform regulatory or
clinical decisions on the benefits and risks of the exposures under
investigation. This warning should accompany any use of the
results from these studies and they should be used accordingly.
The views expressed in this article are the personal views of the
authors and should not be understood or quoted as being made
on behalf of or reflecting the position of the agencies or organisa-
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